TrialArthritis research & therapy2018

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Philip Helliwell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.